Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Blood (2025) 146 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2025-2385

Published: 2025

Journal Articles

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Blood (2025) 146 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2025-1837

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Blood (2025) 146 (Supplement 1): 5521.

https://doi.org/10.1182/blood-2025-5521

Published: 2025

Journal Articles

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Karan Chohan, James Godfrey, Steven Bair, Lorenzo Falchi, Manali Kamdar, Ajay Major, Sonia Godbole, Gilles Salles, Omnia Farahat, Amy Ayers, Ayushi Chauhan, Alex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha

Blood (2025) 146 (Supplement 1): 5520.

https://doi.org/10.1182/blood-2025-5520

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study

Narendranath Epperla, Geoffrey Shouse, Jess Hatfield, Kanithra Sekaran, Yun Choi, Aishwarya Sannareddy, Bryce Bowler, Zain El-amir, Ly Do, Matthew Savas, Taylor Kujawa, Priyanka Pophali, Yasmin Karimi, Mengyang Di, Praveen Ramakrishnan Geethakumari, Yazeed Sawalha, Reem Karmali, Natalie Grover, Adam Olszewski

Blood (2025) 146 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2025-4534

Published: 2025

Journal Articles

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Alyssa Kassouf, Rina Welkie, Yazeed Sawalha, Audrey Sigmund, Timothy Voorhees, Yun Choi, Robert Baiocchi, Jordan Lundberg, Tracy Wiczer, Tyler Everhardt, Caitlyn Crawford, Rebecca Evers, Lindsay Rosen, Beth Christian, Kami Maddocks, David Bond

Blood (2025) 146 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2025-4526

Published: 2025

Journal Articles

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Blood (2025) 146 (Supplement 1): 4515.

https://doi.org/10.1182/blood-2025-4515

Published: 2025

Journal Articles

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Blood (2025) 146 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2025-5384

Published: 2025

Journal Articles

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

Blood (2025) 146 (Supplement 1): 6294.

https://doi.org/10.1182/blood-2025-6294

Published: 2025

Journal Articles

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Blood (2025) 146 (Supplement 1): 1935.

https://doi.org/10.1182/blood-2025-1935

Published: 2025

Journal Articles

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

Blood (2025) 146 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2025-3739

Published: 2025

Journal Articles

Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study

Blood (2025) 146 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2025-1967

Published: 2025

Journal Articles

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 784.

https://doi.org/10.1182/blood-2025-784

Published: 2025

Journal Articles

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

XI Yang, Henry Dumke, Joseph Schroers-Martin, Yazeed Sawalha, Sree Lanka, Izel Okcu, Grzegorz Nowakowski, Peter Doukas, Reem Karmali, Meryl Colton, Michael Spinner, Vincenzo Pizzuti, Manali Kamdar, Olutobi Adewale, Yun Kyoung Tiger, Kelsey Baron, Allison Bock, Marcus Geer, Yasmin Karimi

Blood (2025) 146 (Supplement 1): 783.

https://doi.org/10.1182/blood-2025-783

Published: 2025

Journal Articles

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Timothy Voorhees, Rina Welkie, Hemalatha Rao, Yazeed Sawalha, David Bond, Audrey Sigmund, Yun Choi, John Reneau, Walter Hanel, Polina Shindiapina, Jonathan Brammer, Beth Christian, Lapo Alinari, Nancy Bartlett, Kami Maddocks, Robert Baiocchi

Blood (2025) 146 (Supplement 1): 8240.

https://doi.org/10.1182/blood-2025-8240

Published: 2025

Journal Articles

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Yazeed Sawalha, Marie Hu, Rina Welkie, Aubree Shoemaker, Yun Choi, Audrey Sigmund, Timothy Voorhees, David Bond, John Reneau, Lapo Alinari, Jonathan Brammer, Beth Christian, Robert Baiocchi, Veronika Bachanova, Kami Maddocks

Blood (2025) 146 (Supplement 1): 8239.

https://doi.org/10.1182/blood-2025-8239

Published: 2025

Journal Articles

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

Blood (2025) 146 (Supplement 1): 464.

https://doi.org/10.1182/blood-2025-464

Published: 2025

Journal Articles

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Blood (2025) 146 (Supplement 1): 3663.

https://doi.org/10.1182/blood-2025-3663

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Evaluation of real-world outcomes with zanubrutinib in patients with marginal zone lymphoma: Results from multicenter cohort study

Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study

Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only